Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>Events>This Event
  Events - October 2012

The importance of (Bio) Pharmaceutical properties in Successful Drug Design

04 Oct 2012 - 04 Oct 2012 - NHLI, Kensington, London

Bookmark and Share

The pressing challenge pharmaceutical scientists can often be faced with is dealing with drug development candidate molecules with sub-optimal drug delivery or pharmaceutical properties. This symposium brings together international experts from both the pharmaceutical industry and academia to discuss (bio)pharmaceutical properties and strategies to optimise pharmaceutical development and minimise development impact. Small molecule NCE topics include a formulation road map for oral delivery, assessment of CMC developability using material efficiency indices, preclinical assessment of amorphous solid dispersion and case studies of the use of in the development of compounds with poor aqueous solubility, and new insights into the solubilisation, supersaturation and precipitation behaviour of APIs. Biopharmaceutical topics will include microparticle-protein interactions and strategies for optimising delivery and PK of biopharmaceuticals.

Session 1 : Introduction and Chair - Dr Andrew Ratcliffe, Cellzome
10.00   Prof Graham Buckton, Pharmaterials
The form and the formulation - strategy for oral delivery
10.50Dr Andrey Peresypkin, Vertex, USA
Pre-Clinical assessment of CMC developability of drug candidates by using material efficiency indices as the integral part of the translational product development strategy
11.40Dr Mark Saunders, Kuecept
Preclinical assessment of amorphous solid dispersions: friend or foe?

Session 2 : Chair - Dr Mo Alavijeh, Pharmidex

13.40Dr David Lyon, Bends Research, USA 
Use of amorphous dispersions in the development of compounds with poor aqueous solubility: Case studies from discovery to commercial
14.30Mr Karl Box, Sirius
Small-scale solubility and dissolution assays; new insights into solubilisation, supersaturation and precipitation behaviour of APIs
Session 3 : Chair - Dr Kate Brown, Imperial

Prof Ted Randolp, Centre for Pharmaceutical Biotechnology, USA
Microparticle-Protein interactions: Conformation, cavitation and immune response

16.30Dr Barry Moore, Xstalbio
Strategies for improving delivery, targeting and PK of Biopharmaceuticals

Further information
Scientific News
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Speeding Up the Process of Making Vaccines
System uses a freeze-dry concept to develop "just-add-water" solution.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
New Method Identifies Up to Twice as Many Proteins and Peptides
An international team of researchers developed a method that identifies up to twice as many proteins and peptides in mass spectrometry data than conventional approaches.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.
Novel Stem Cell Line Avoids Risk of Introducing Transplanted Tumors
Progenitor cells might eventually be used to repair or rebuild damaged or destroyed organs.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos